AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Celularity and DefEYE Partner to Advance Regenerative Therapies in Eye Care with Exclusive License Agreement and In-Kind Investment.
ByAinvest
Thursday, Oct 30, 2025 8:51 am ET1min read
Celularity and DefEYE, Inc. have partnered to advance the growth of regenerative therapies in eye care. DefEYE will launch and scale a portfolio of decellularized biologic solutions for eye care, including Biovance, Interfyl, and collaborative research and development for future commercial products. Celularity granted DefEYE an exclusive sublicense to its ophthalmic biologics portfolio and will be the exclusive contract manufacturer for DefEYE's portfolio of ophthalmic biologics solutions. The partnership aims to drive innovation and access new markets for Celularity's portfolio of commercial products.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet